Phathom Pharmaceuticals (PHAT) Scheduled to Post Quarterly Earnings on Thursday

Phathom Pharmaceuticals (NASDAQ:PHAT) is scheduled to be issuing its quarterly earnings data before the market opens on Thursday, November 7th. Analysts expect the company to announce earnings of ($1.57) per share for the quarter. Individual that are interested in participating in the company’s earnings conference call can do so using this link.

Phathom Pharmaceuticals (NASDAQ:PHAT) last issued its quarterly earnings data on Thursday, August 8th. The company reported ($1.35) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.39) by $0.04. The company had revenue of $7.32 million for the quarter, compared to analyst estimates of $5.65 million. On average, analysts expect Phathom Pharmaceuticals to post $-6 EPS for the current fiscal year and $-5 EPS for the next fiscal year.

Phathom Pharmaceuticals Stock Performance

PHAT stock opened at $18.37 on Wednesday. The stock’s 50 day moving average price is $17.20 and its 200 day moving average price is $13.17. The firm has a market cap of $1.09 billion, a P/E ratio of -3.58 and a beta of 0.72. Phathom Pharmaceuticals has a 1 year low of $6.07 and a 1 year high of $19.71.

Analysts Set New Price Targets

Several analysts have recently issued reports on PHAT shares. Needham & Company LLC restated a “buy” rating and issued a $26.00 price objective on shares of Phathom Pharmaceuticals in a research report on Friday, September 13th. The Goldman Sachs Group raised their price target on shares of Phathom Pharmaceuticals from $10.00 to $12.00 and gave the stock a “neutral” rating in a research note on Friday, August 9th. Finally, HC Wainwright reiterated a “buy” rating and set a $28.00 price target on shares of Phathom Pharmaceuticals in a report on Monday, August 12th.

About Phathom Pharmaceuticals

Phathom Pharmaceuticals, Inc, biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada for an investigational potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach.